PERSONAL INFORMATION

Silvia Zappavigna

via San Felice 184 Palma Campania (NA) 80036

+39 3299246113

silvia.zappavigna@unicampania.it

Sex Female | Date of birth 12th August 1982 | Nationality Italian

WORK EXPERIENCE

(from - to)

DECEMBER 2019-today Assistant Professor at the Department of Precision Medicine, University of Campania "L. Vanvitelli"

OCTOBER 2018-2024 National Scientific Enabling as Associate Professor of Biochemistry

JANUARY 2011-JULY 2019 Research grant at the Department of Precision Medicine, University of Campania "L. Vanvitelli"

SEPTEMBER 2007-2008 Post-doc fellow at the Department of Pharmaceutical Chemistry and Toxicology, University of Naples Federico II.

EDUCATION AND TRAINING

(from - to)

DECEMBER 2014 PhD in Food and Health: biotechnologies and methodologies applied to digestive physiopathology. Score: excellent

MAY 2012 Specialization in Clinical Biochemistry. Score 50/50 cum laude

OCTOBER 2006 Bachelor of Sc. in Biothecnology.Thesis Title: "Role of IFN beta in pancreatic tumor". Score: 110/110 cum laude.

JULY 2001 High school graduation. Score 100/100.

Mother tongue(s) Italian

Other language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C2	C2	C2	C2	C2

ADDITIONAL INFORMATION

AWARDS

Poster Award, AICC 2009, Dec. 2-4, Firenze, Italy

PhD thesis Award, Accademia Ercolanese, December 2015, Caserta, Italy

FINANCIAL SUPPORTS AND COOPERATIONS

7/02/2017 Financial Support received by Consorzio Oncotech for a project entitled “LANZA Study – Circulating tumor cells count in patients with prostate cancer receiving enzalutamide” (10.000 euro)

12/07/2017 Financial Support received by Consorzio Oncotech for a project entitled “CABAzitaxel with or without prednisone in patients with metastatic CAstration REsistant prostate cancer (mCRPC) progressed during or after a previous docetaxel-based chemotherapy: a multi-center, prospective, two-arm, open label, non inferiority phase II study.” (20.000 euro)

01/09/2020 Financial support received in the Research program VALERE 2020 by University of Campania for a project entitled “Nanotech revolution for miRNA delivery: a new tool to overcome glioblastomanchemoresistance by targeting MGMT and HMGA1/2” (26,700 euro)

Reviewer activity for the following peer reviewed international journals.
-Acta Biochimica et Biophysica Sinica
- Journal of Women's Health, Issues and Care
-Scientific reports
-Biotechnology avances

Editorial Board Member ofpeer reviewed international journals.
Section editor in Nanobiotecnology for World Cancer research Journal
-Insights in Breast Cancer OPR Science"
-Translational Medicine Reports" Page press

PUBBLICATIONS IN EXTENSO:81

H-INDEX:28; TOTAL CITATIONS : 2324 (SCOPUS)

RELEVANT PUBLICATIONS

1: Della Corte CM, Barra G, Ciaramella V, Di Liello R, Vicidomini G, Zappavigna S, Luce A, Abate M, Fiorelli A, Caraglia M, Santini M, Martinelli E, Troiani T, Ciardiello F, Morgillo F. Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures. J Exp Clin Cancer Res. 2019 Jun 13;38(1):253. doi: 10.1186/s13046-019-1257-1. I.F:5.6 Q1

2: Zappavigna S, Vanacore D, Lama S, Potenza N, Russo A, Ferranti P, Dallio M, Federico A, Loguercio C, Sperlongano P, Caraglia M, Stiuso P. Silybin-Induced Apoptosis Occurs in Parallel to the Increase of Ceramides Synthesis and miRNAs Secretion in Human Hepatocarcinoma Cells. Int J Mol Sci. 2019 May 3;20(9). pii: E2190. doi: 10.3390/ijms20092190. I.F:4.18 Q2

3: Giarra S, Zappavigna S, Campani V, Abate M, Cossu AM, Leonetti C, Porru M, Mayol L, Caraglia M, De Rosa G. Chitosan-Based Polyelectrolyte Complexes for Doxorubicin and Zoledronic Acid Combined Therapy to Overcome Multidrug Resistance. Pharmaceutics. 2018 Oct 9;10(4). pii: E180. doi: 10.3390/ pharmaceutics10040180. (co-first author) I.F:4.77 Q1

4: Potenza N, Mosca N, Zappavigna S, Castiello F, Panella M, Ferri C, Vanacore D,Giordano A, Stiuso P, Caraglia M, Russo A. MicroRNA-125a-5p Is a Downstream Effector of Sorafenib in Its Antiproliferative Activity Toward Human Hepatocellular Carcinoma Cells. J Cell Physiol. 2017 Jul;232(7):1907-1913. doi: 10.1002/jcp.25744. I.F:4.52 Q1-Q2

5: Zappavigna S, Scuotto M, Cossu AM, Ingrosso D, De Rosa M, Schiraldi C, Filosa R, Caraglia M. The 1,4 benzoquinone-featured 5-lipoxygenase inhibitor RF-Id induces apoptotic death through downregulation of IAPs in human glioblastoma cells. J Exp Clin Cancer Res. 2016 Oct 22;35(1):167.
I.F:5.6 Q1

6: Salzano G, Zappavigna S, Luce A, D'Onofrio N, Balestrieri ML, Grimaldi A, Lusa S, Ingrosso D, Artuso S, Porru M, Leonetti C, Caraglia M, De Rosa G. Transferrin-Targeted Nanoparticles Containing Zoledronic Acid as a Potential Tool to Inhibit Glioblastoma Growth. J Biomed Nanotechnol. 2016 Apr;12(4):811-30.(co-first author) I.F:5.06 Q1-Q2

7: Stiuso P, Potenza N, Lombardi A, Ferrandino I, Monaco A, Zappavigna S, Vanacore D, Mosca N, Castiello F, Porto S, Addeo R, Prete SD, De Vita F, Russo A, Caraglia M. MicroRNA-423-5p Promotes Autophagy in Cancer Cells and Is Increased in Serum From Hepatocarcinoma Patients Treated With Sorafenib. Mol Ther Nucleic Acids. 2015 Mar 17;4:e233. doi: 10.1038/mtna.2015.8. I.F:5.91 Q1

8: Ilisso CP, Castellano M, Zappavigna S, Lombardi A, Vitale G, Dicitore A, Cacciapuoti G, Caraglia M, Porcelli M. The methyl donor S-adenosylmethionine potentiates doxorubicin effects on apoptosis of hormone-dependent breast cancer cell lines. Endocrine. 2015 Sep;50(1):212-22. doi: 10.1007/s12020- 014-0484-7. Epub 2015 Jan 11. Erratum in: Endocrine. 2016 Sep;53(3):875. (corresponding author)

I.F:3.9 Q2

9: Porru M, Zappavigna S, Salzano G, Luce A, Stoppacciaro A, Balestrieri ML, Artuso S, Lusa S, De Rosa G, Leonetti C, Caraglia M. Medical treatment of orthotopic glioblastoma with transferrin- conjugated nanoparticles encapsulating zoledronic acid. Oncotarget. 2014 Nov 15;5(21):10446-59.
I.F:5.16 Q1

10: Franco R, Zappavigna S, Gigantino V, Luce A, Cantile M, Cerrone M, Facchini G, Perdonà S, Pignata S, Di Lorenzo G, Chieffi S, Vitale G, De Sio M, Sgambato A, Botti G, Yousif AM, Novellino E, Grieco P, Caraglia M. Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion. J Exp Clin Cancer Res. 2014 Jun 3;33:48. doi: 10.1186/1756-9966-33-48. (co-first author) I.F:5.6 Q1

11: Lamberti M, Zappavigna S, Sannolo N, Porto S, Caraglia M. Advantages and risks of nanotechnologies in cancer patients and occupationally exposed workers. Expert Opin Drug Deliv. 2014 Jul;11(7):1087-101. doi: 10.1517/17425247.2014.913568. Epub 2014 Apr 29. Review. (co-first author) I.F:5.4 Q1

12: Federico A, Zappavigna S, Romano M, Grieco P, Luce A, Marra M, Gravina AG, Stiuso P, D'Armiento FP, Vitale G, Tuccillo C, Novellino E, Loguercio C, Caraglia M. Urotensin-II receptor is over-expressed in colon cancer cell lines and in colon carcinoma in humans. Eur J Clin Invest. 2014;44(3):285-94. doi: 10.1111/eci.12231. Epub 2014 Jan 22. (co-first author) I.F:2.78 Q1

13: Troiani T, Zappavigna S, Martinelli E, Addeo SR, Stiuso P, Ciardiello F, Caraglia M. Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. Expert Opin Biol Ther. 2013 Feb;13(2):241-55. doi: 10.1517/14712598.2012.756469. Epub 2013 Jan 3. Review. (co-first author) I.F:3.58 Q1-Q2

14: Lamberti M, Porto S, Marra M, Zappavigna S, Grimaldi A, Feola D, Pesce D, Naviglio S, Spina A, Sannolo N, Caraglia M. 5-Fluorouracil induces apoptosis in rat cardiocytes through intracellular oxidative stress. J Exp Clin Cancer Res. 2012 Jul 19;31:60. doi: 10.1186/1756-9966-31-60. I.F:5.6 Q1

15: Vitale G, Zappavigna S, Marra M, Dicitore A, Meschini S, Condello M, Arancia G, Castiglioni S, Maroni P, Bendinelli P, Piccoletti R, van Koetsveld PM, Cavagnini F, Budillon A, Abbruzzese A, Hofland LJ, Caraglia M. The PPAR-g agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-b treated pancreatic cancer cells. Biotechnol Adv. 2012 Jan- Feb;30(1):169-84. doi: 10.1016/ j.biotechadv.2011.08.001. Epub 2011 Aug 17. I.F:12.8 Q1

16: Marra M, Salzano G, Leonetti C, Porru M, Franco R, Zappavigna S, Liguori G,Botti G, Chieffi P, Lamberti M, Vitale G, Abbruzzese A, La Rotonda MI, De Rosa G, Caraglia M. New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study. Biotechnol Adv. 2012 Jan-Feb;30(1):302-9. doi: 10.1016/j.biotechadv.2011.06.018. I.F:12.8 Q1

17: Donadelli M, Dando I, Zaniboni T, Costanzo C, Dalla Pozza E, Scupoli MT, Scarpa A, Zappavigna S, Marra M, Abbruzzese A, Bifulco M, Caraglia M, Palmieri M. Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS- mediated mechanism. Cell Death Dis. 2011 Apr 28;2:e152. doi:10.1038/ cddis.2011.36. I.F:5.95 Q1

18: Ostacolo L, Marra M, Ungaro F, Zappavigna S, Maglio G, Quaglia F, Abbruzzese A, Caraglia M. In vitro anticancer activity of docetaxel-loaded micelles based on poly(ethylene oxide)-poly(epsilon- caprolactone) block copolymers: Do nanocarrier properties have a role? J Control Release. 2010 Dec 1;148(2):255-63. doi: 10.1016/ j.jconrel.2010.08.006. Epub 2010 Sep 8. I.F:7.9 Q1

19: Marra M, Santini D, Meo G, Vincenzi B, Zappavigna S, Baldi A, Rosolowski M,Tonini G, Loeffler M, Lupu R, Addeo SR, Abbruzzese A, Budillon A, Caraglia M. Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells. Int J Cancer. 2009 Nov 1;125(9):2004-13. doi: 10.1002/ijc.24648. I.F:4.9 Q1

20: Marra M, Salzano G, Leonetti C, Tassone P, Scarsella M, Zappavigna S, Calimeri T, Franco R, Liguori G, Cigliana G, Ascani R, La Rotonda MI, Abbruzzese A, Tagliaferri P, Caraglia M, De Rosa G. Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes. Nanomedicine. 2011 Dec;7(6):955-64. doi: 10.1016/j.nano.2011.03.004. Epub 2011 Mar 29. I.F:5.57 Q1

21:Zappavigna S, Abate M, Cossu AM, et al. Urotensin-II-Targeted Liposomes as a New Drug Delivery System towards Prostate and Colon Cancer Cells. J Oncol. 2019;2019:9293560.

22:Salzano G, Marra M, Porru M, Zappavigna S, Abbruzzese A, La Rptonda MI, Leonetti C, Caraglia M, De Rosa G. Self-assembly nanoparticles for the delivery of bisphosphonates into tumors. Int J Pharm. 2011, 403:292-7.

Napoli 12-01-2022 Silvia Zappavigna